{"id":5479,"date":"2026-01-17T01:06:28","date_gmt":"2026-01-16T22:06:28","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=5479"},"modified":"2026-01-17T01:06:30","modified_gmt":"2026-01-16T22:06:30","slug":"atossa-therapeutics-receives-fda-orphan-drug-designation-for-z-endoxifen-for-the-treatment-of-duchenne-muscular-dystrophy","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/pt\/atossa-therapeutics-receives-fda-orphan-drug-designation-for-z-endoxifen-for-the-treatment-of-duchenne-muscular-dystrophy\/","title":{"rendered":"Atossa Therapeutics recebe a designa\u00e7\u00e3o de medicamento \u00f3rf\u00e3o FDA para (Z)-Endoxifen para o tratamento da distrofia muscular de Duchenne."},"content":{"rendered":"<p class=\"wp-block-paragraph\">A Atossa Therapeutics anunciou que o Escrit\u00f3rio de Desenvolvimento de Produtos \u00d3rf\u00e3os da Administra\u00e7\u00e3o de Alimentos e Medicamentos dos EUA (\u201cFDA\u201d) concedeu a designa\u00e7\u00e3o de medicamento \u00f3rf\u00e3o ao (Z)-endoxifen para o tratamento da distrofia muscular de Duchenne (\u201cDMD\u201d). &gt;&gt; <strong>Saber mais:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/pt\/atossa-therapeutics-receives-fda-rare-pediatric-disease-designation-for-z-endoxifen-for-duchenne-muscular-dystrophy\/\" target=\"_blank\" data-type=\"link\" data-id=\"https:\/\/dmdwarrior.com\/atossa-therapeutics-receives-fda-rare-pediatric-disease-designation-for-z-endoxifen-for-duchenne-muscular-dystrophy\/\" rel=\"noreferrer noopener\">Atossa Therapeutics recebe a designa\u00e7\u00e3o de doen\u00e7a pedi\u00e1trica rara FDA para (Z)-Endoxifen<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cAl\u00e9m da designa\u00e7\u00e3o de Doen\u00e7a Pedi\u00e1trica Rara j\u00e1 recebida, a Designa\u00e7\u00e3o de Medicamento \u00d3rf\u00e3o para o (Z)-endoxifen na distrofia muscular de Duchenne \u00e9 um marco importante para a Atossa, \u00e0 medida que avan\u00e7amos no desenvolvimento do (Z)-endoxifen para esta doen\u00e7a grave e debilitante\u201d, observou Steven C. Quay, MD, Ph.D., Presidente e Diretor Executivo da Atossa Therapeutics.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A Atossa planeja continuar interagindo com a FDA \u00e0 medida que avan\u00e7a nos esfor\u00e7os de desenvolvimento e fornecer\u00e1 atualiza\u00e7\u00f5es conforme necess\u00e1rio.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Siga esta p\u00e1gina<\/strong>&nbsp;&gt;&gt;&gt;&nbsp;<a href=\"https:\/\/dmdwarrior.com\/pt\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Todos os ensaios cl\u00ednicos para distrofia muscular de Duchenne<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Atossa Therapeutics, announced that the U.S. Food and Drug Administration (&#8220;FDA&#8221;) Office of Orphan Products Development has granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dystrophy (&#8220;DMD&#8221;). >> Learn More: Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen &#8220;In addition to the previously received Rare Pediatric Disease designation, Orphan [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5480,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[461,462,464,463],"class_list":["post-5479","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-z-endoxifen","tag-atossa-therapeutics","tag-endoxifen","tag-tamoxifen"],"subtitle":"A Atossa Therapeutics anunciou que a FDA concedeu a designa\u00e7\u00e3o de medicamento \u00f3rf\u00e3o \u00e0 (Z)-endoxifen para o tratamento da distrofia muscular de Duchenne.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/5479","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/comments?post=5479"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/5479\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media\/5480"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media?parent=5479"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/categories?post=5479"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/tags?post=5479"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}